The Bombay High Court has refused to grant an interim injunction to Sun Pharmaceutical Industries Limited, allowing Meghmani Lifesciences Limited to continue using the trademark “EsiRaft” for its pharmaceutical product. The court found that the mark is not deceptively similar to Sun Pharma’s “RACIRAFT” and that there is no likelihood of confusion between the two marks. <\/p>\n
Sun Pharma had filed a trademark infringement and passing off suit against Meghmani Lifesciences, claiming that the use of “EsiRaft” infringed on its goodwill and was likely to cause confusion among consumers. However, the court held that the marks are visually and phonetically dissimilar and that the element “RAFT” is descriptive of the product’s characteristics and cannot be used to establish deceptive similarity.<\/p>\n
The court also noted that the prefixes “RACI” and “ESI” are distinct and that Meghmani Lifesciences’ adoption of the mark was bona fide. The company had explained that “ESI” referred to “Enhanced System Improvement” and “Esophageal Symptom Index”. The court observed that the use of two-color combinations on the packaging was common in the trade and was insufficient to establish infringement.<\/p>\n
The court applied the principles of trademark law, including the anti-dissection rule, the viewpoint of an average consumer with imperfect recollection, and the likelihood of confusion. It found that the competing marks are prima facie visually and phonetically dissimilar and will not create any confusion in the minds of consumers.<\/p>\n
In dismissing Sun Pharma’s interim injunction plea, the court held that the company had failed to make out a prima facie case of trademark infringement or passing off. The court also vacated an earlier ex-parte ad-interim injunction that had restrained Meghmani Lifesciences from using the disputed mark. The decision allows Meghmani Lifesciences to continue using the “EsiRaft” mark for its product, which is used to treat heartburn and indigestion. <\/p>\n
The case highlights the importance of careful consideration of trademark similarity and the need for companies to establish a strong case of infringement or passing off in order to obtain an interim injunction. The court’s decision is significant, as it allows Meghmani Lifesciences to continue marketing its product without interruption, while also protecting the rights of Sun Pharma to pursue its claims in the main suit. <\/p>\n
The court’s observation that the get-up of the marks itself is different and the overall visual appearance of the rival products is dissimilar, is crucial in determining the likelihood of confusion. The decision also emphasizes the need for companies to ensure that their trademarks are distinctive and do not infringe on the rights of other companies. <\/p>\n
In conclusion, the Bombay High Court’s decision in this case provides guidance on the principles of trademark law and the factors that are considered in determining the likelihood of confusion between two marks. The decision is a significant one, as it allows Meghmani Lifesciences to continue using the “EsiRaft” mark, while also protecting the rights of Sun Pharma to pursue its claims in the main suit.<\/p>\n","protected":false},"excerpt":{"rendered":"
The Bombay High Court has refused to grant an interim injunction to Sun Pharmaceutical Industries Limited, allowing Meghmani Lifesciences Limited to continue using the trademark “EsiRaft” for its pharmaceutical product. The court found that the mark is not deceptively similar to Sun Pharma’s “RACIRAFT” and that there is no likelihood of confusion between the two […]<\/p>\n","protected":false},"author":1,"featured_media":88143,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[2,16],"tags":[],"class_list":["post-89743","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma","category-sun-pharma"],"jetpack_featured_media_url":"https:\/\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89757,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/06\/sun-pharmaceutical-industries-suffers-loss-in-trademark-dispute-as-bombay-high-court-rules-esiraft-and-raciraft-do-not-bear-deceptive-similarities\/","url_meta":{"origin":89743,"position":0},"title":"Sun Pharmaceutical Industries suffers loss in trademark dispute as Bombay High Court rules EsiRaft and Raciraft do not bear deceptive similarities.","author":"Team Small News","date":"January 6, 2026","format":false,"excerpt":"The Bombay High Court has ruled in favor of Eris Lifesciences, dismissing Sun Pharmaceutical's claim that Eris's medication \"EsiRaft\" infringed on Sun Pharma's trademark for their medication \"Raciraft\". The court found that the names \"EsiRaft\" and \"Raciraft\" are not deceptively similar, and therefore, Eris Lifesciences did not infringe on Sun\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":89721,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/30\/delhi-high-court-prohibits-dr-reddys-from-using-the-sun-trademark-on-sunscreen-product-labels\/","url_meta":{"origin":89743,"position":1},"title":"Delhi High Court prohibits Dr. Reddy’s from using the ‘SUN’ trademark on sunscreen product labels.","author":"Team Small News","date":"December 30, 2025","format":false,"excerpt":"The Delhi High Court has issued a restraining order against Dr. Reddy's Laboratories, preventing the company from using the 'SUN' mark on their sunscreen product labels. This decision comes after a lawsuit was filed by Sun Pharmaceutical Industries, which claimed that Dr. Reddy's was infringing on their trademark rights. Sun\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89748,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/04\/delhi-high-court-bars-dr-reddys-from-producing-venusia-sunscreens-bearing-the-sun-logo\/","url_meta":{"origin":89743,"position":2},"title":"Delhi High Court bars Dr Reddy’s from producing VENUSIA sunscreens bearing the SUN logo.","author":"Team Small News","date":"January 4, 2026","format":false,"excerpt":"The Delhi High Court has issued an interim order restraining Dr. Reddy's Laboratories from manufacturing and selling its VENUSIA sunscreens with a label that includes the word \"SUN\". The court's decision comes in response to a lawsuit filed by Glenmark Pharmaceuticals, which claims that Dr. Reddy's is infringing on its\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89871,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/28\/sun-pharma-receives-green-light-for-obesity-treatment-injection-similar-to-wegovy\/","url_meta":{"origin":89743,"position":3},"title":"Sun Pharma receives green light for obesity treatment injection similar to Wegovy.","author":"Team Small News","date":"January 28, 2026","format":false,"excerpt":"Sun Pharmaceutical Industries has received approval for a weight loss injection similar to Novo Nordisk's Wegovy. The new treatment, called \"SUN-144\", is a once-weekly injection that helps with weight management in adults with obesity or overweight with at least one weight-related condition. This approval marks a significant milestone for Sun\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":89821,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/19\/sun-pharma-sets-sights-on-10-billion-organon-takeover-to-bolster-us-presence\/","url_meta":{"origin":89743,"position":4},"title":"Sun Pharma Sets Sights on $10 Billion Organon Takeover to Bolster US Presence","author":"Team Small News","date":"January 19, 2026","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd., India's largest drug manufacturer, is considering a monumental acquisition of Organon, a US-based company specializing in women's health and biosimilars. The potential deal, valued at $10 billion, is being led by the company's founder, Dilip Shanghvi. If successful, this acquisition would be a significant milestone for\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":89753,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/05\/national-pharmaceutical-pricing-authority-caps-retail-price-of-sun-pharmas-gemcitabine-injections\/","url_meta":{"origin":89743,"position":5},"title":"National Pharmaceutical Pricing Authority Caps Retail Price of Sun Pharma’s Gemcitabine Injections","author":"Team Small News","date":"January 5, 2026","format":false,"excerpt":"The National Pharmaceutical Pricing Authority (NPPA) has set the retail price for Sun Pharma's Gemcitabine injections. Gemcitabine is a chemotherapy medication used to treat various types of cancer, including pancreatic, breast, ovarian, and non-small cell lung cancer. The NPPA, which is responsible for regulating the prices of pharmaceutical products in\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89743"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89743\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media\/88143"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}